FDA Accepts Takeda's Oveporexton NDA, Grants Priority Review for Narcolepsy Type 1

The FDA accepted Takeda's new drug application for oveporexton, an investigational orexin 2 receptor (OX2R)-selective agonist for the treatment of narcolepsy type 1, and granted priority review. The agency has set a Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2026.

Oveporexton is designed to restore orexin signaling in patients with narcolepsy type 1, a condition characterized by the loss of orexin-producing neurons that regulate wakefulness and arousal. This loss contributes to excessive daytime sleepiness and disrupted sleep-wake regulation.

The investigational therapy represents a shift from current treatment approaches. Currently available treatments offer symptom relief but do not address the underlying cause of the disease. Oveporexton is designed to restore orexin signaling, positioning it as an orexin-restorative approach beyond symptomatic management.

Narcolepsy type 1 is a relentless disease that can have a debilitating impact on a person's everyday life from work and school to social interactions. If approved, oveporexton would offer people living with narcolepsy type 1 and their health care providers a new approach to the way the disease is treated.

The orexin system plays a critical role in regulating wakefulness and arousal in the brain. By stimulating orexin receptors, therapies like oveporexton aim to restore wake-promoting signaling and improve daytime alertness, representing a disease-targeted approach for narcolepsy and related hypersomnolence disorders.